Accedi ai contenuti
Registrati »
Accedi ai contenuti
Registrati »

Objectives: The aim of this study was to assess the cost effectiveness of midostaurin + cytarabine + daunorubicin (midostaurin arm) versus placebo + cytarabine + daunorubicin (placebo arm) in the treatment of adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) who are eligible for standard cytarabine + daunorubicin chemotherapy, from a US third-party payer perspective. Methods: A lifetime partitioned

PharmacoEconomics 2019; 37:239.  /  Stein E, Xie J, Duchesneau E, et al.

Outcomes of pediatric and young adult patients diagnosed with acute lymphoblastic leukemia (ALL) have improved significantly in the past few decades. Treatment advances have provided 5-year survival rates ranging from 78 to 91% depending on the age at diagnosis. However, approximately 2-3% of patients will present with refractory disease that

Blood Cancer J 2019; 22;9(2):10. /  Hucks G, Rheingold SR

Healthcare costs are rising due to an increase in chronic diseases, including chronic myeloid leukemia (CML) due to improved survival. In CML care, patient adherence and physician adherence are key elements. We assessed the potential health gain and cost savings when both are improved, using a decision analytic model that

Leuk Lymphoma 2019; 22:1-8. /  Ector GI, Govers, Westerweel PE, et al.

Background: The WHO defined myeloid and lymphoid neoplasms (MLN) with eosinophilia associated with PDGFRB, PDGFRA, FGFR1 rearrangements as a new entity in 2016. PDGFRB-rearranged MLN sensitive to imatinib were described in adult patients. We report the first pediatric patient with PDGFRB-rearranged myeloproliferative disorder associated with T-lymphoblastic lymphoma bearing the t(5; 14)(q33;q32) translocation

Acta Haematol 2019;141(2):119-127. /  Bielorai B, Leitner M, Goldstein G

Background: Healthcare systems and policy makers worldwide are demonstrating interest in shared decision making, which requires patient activation. Patient activation can be measured using a validated tool called the patient activation measure-10. First cycle comprehensive chemotherapy consultation services (3CS) is provided by an oncology pharmacy team member during a patient

J Oncol Pharm Pract  2019 Feb 26. [Epub ahead of print] /  Bates JS, Auten J, Sketch MR, et al.

Background: The inclusion of future medical costs in cost-effectiveness analyses remains a controversial issue. The impact of capturing future medical costs is likely to be particularly important in patients with cancer where costly lifelong medical care is necessary. The lack of clear, definitive pharmacoeconomic guidelines can limit comparability and has

Pharmacoeconomics 2019 Mar 13. [Epub ahead of print] /  Tew M,  Clarke P, Karin Thursky K, et al.

Chimeric antigen receptor (CAR) modified T cells targeted to CD19 have resulted in unprecedented remission rates for adult and pediatric patients with relapsed and refractory B cell acute lymphoblastic leukemia (ALL). With regulatory approval for tisagenlecleucel and many other agents under active investigation, the use of CAR T cells for

Am J Hematol 2019 Feb 19. [Epub ahead of print] /  Frey NV

Background: Medication communication and prescribing on the post-take ward round following patient admission to hospital can be suboptimal leading to worse patient outcomes. Objective To evaluate the impact of clinical pharmacist participation on the post-take ward round on the appropriateness of medication prescribing, medication communication, and overall patient health care outcomes. Setting Tertiary referral teaching

International Journal of Clinical Pharmacy 2019;41(1):65-73. /  Bullock B, Donovan P, Mitchell C, et al.

Studies of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia (CLL) have demonstrated the potential to produce deep remissions-and possibly cures-in some patients with heavily pretreated, high-risk, relapsed, and refractory disease. Unfortunately, most clinical trials of CAR T cells in CLL report complete responses only in the minority

Am J Hematol 2019 Mar 12. [Epub ahead of print] /  Bair SM, Porter DL.

Materials and methods: A retrospective study was conducted during two periods: a baseline period from December 2015 to June 2016 and an intervention period from July 2016 to February 2017. The investigational drug service (IDS) pharmacists performed active interventions during the intervention period. Results: Among 12,387 investigational drug orders, 395 (6.1%)

Journal of Oncology Pharmacy Practice 2019 March 4. [Epub ahead of print] /  Moon JY, Lee Y, Han J. M., et al.